The European Medicines Agency alerted by a …

The European Medicines Agency (EMA) warned of new side effect of coronavirus vaccine AstraZeneca, and noted that “should not be vaccinated with Vaxzevria” people who have previously suffered from capillary leak syndrome.

The EMA defines this syndrome as “a very rare serious disease that causes fluid loss from small blood vessels (capillaries), which results in swelling mainly of the arms and legs, low blood pressure, thickening of the blood and low levels of albumin in the blood (an important protein in the blood) ”.

Currently, the cause of this pathology is unknown and there is also no cure, rather it focuses on stabilizing symptoms and preventing serious complications.

In view of this study, the international body has recommended that this syndrome be added to the package leaflet as a new side effect of the vaccine, after confirming “a very small number” of cases after inoculation, and include this warning to educate healthcare professionals and patients about this risk.

This was established by the EMA Safety Committee (PRAC) after “a thorough review of 6 cases of capillary leak syndrome in people who received Vaxzevria ”.

Most of these cases were recorded in women and within four days of vaccination. In addition, three of those affected had a history of capillary leak syndrome and one of them later died.

“The likelihood of this happening is very low, but even so, the symptoms must be known in order to receive prompt medical treatment that helps recovery and avoids complications,” they warned of the EMA.

On the other hand, they requested that if someone gets the vaccine and suffers from rapid swelling of the arms and legs or very sudden weight gain in the days following the vaccination, they inform the doctor.

This new side effect adds to other research on the impact of the vaccine. An expert from the European Medicines Agency (EMA) said last April that there was “a link” between the Astrazeneca vaccine and the cases of thrombosis recorded in those inoculated.

However, the EMA has indicated that it approves the AstraZeneca vaccine, but recognizes that there is a relationship between its administration and the occurrence of a very small number of rare cases of thrombosis in those vaccinated.

Official records show that more than 78 million doses of Vaxzevria have already been supplied in countries including the European Union, Iceland, Great Britain, Norway and Liechtenstein.